Prostate Cell News Volume 1.04 | Feb 5 2010

    0
    36
    Prostate Cell News 1.04, February 5, 2010.
    In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

    TOP STORY

    Evaluation of the Frequency of Putative Prostate Cancer Stem Cells in Primary and Metastatic Prostate Cancer
    In established metastases no single or combination of marker expression profiles identify the established metastatic phenotype, although CD44 expression was shown to be more frequent in metastases that in primary cancers. [Prostate]

    Watch Procedure Now 
    Detect 7x More Prostate Epithelial Progenitor Cells
    with ProstaCult

    by STEMCELL Technologies
     
     
    CLICK HERE TO LEARN HOWSTEMCELL Technologies Inc
     

    SCIENCE NEWS

    Loss of Gene Function Makes Some Prostate Cancer Cells More Aggressive, Researchers Find
    The study in mice found that eliminating the DAB2IP scaffolding in human carcinoma cells caused them to change from epithelial cells to mesenchymal cells – a hallmark of metastatic cancer. [Press release from UT Southwestern Medical Center discussing online prepublication in Proceedings of the National Academy of Sciences]

    Watch Procedure Now 
    Use ALDEFLUOR® to Detect Prostate Precursor Cells
    by STEMCELL Technologies
     
     
    WATCH THE VIDEOSTEMCELL Technologies Inc
     

    CURRENT PUBLICATIONS

    LABORATORY RESEARCH

    Estrogen Receptor-Beta Activated Apoptosis in Benign Hyperplasia and Cancer of the Prostate is Androgen Independent and TNF(Alpha) Mediated
    Data are indicative of the therapeutic potential of estrogen receptor-beta agonist for treatment of prostate cancer and/or benign prostatic hyperplasia with or without androgen withdrawal. [Proc Natl Acad Sci]

    Role of Cationic Channel Transient Receptor Potential Vanilloid 2 (TRPV2) in Promoting Prostate Cancer Migration and Progression to Androgen Resistance
    Researchers report that the nonselective cationic channel transient receptor potential vanilloid 2 is a distinctive feature of castration-resistant prostate cancer. [Cancer Res]

    Variability in the Androgen Response of Prostate Epithelium to 5(Alpha)-Reductase Inhibition: Implications for Prostate Cancer Chemoprevention
    Findings suggest that androgen receptor levels may predict the chemopreventive efficacy of 5(alpha)-reductase inhibitors. [Cancer Res]

    Flavokawain B, a Kava Chalcone, Exhibits Robust Apoptotic Mechanisms on Androgen Receptor-Negative, Hormone-Refractory Prostate Cancer Cell Lines and Reduces Tumor Growth in a Preclinical Model
    Resarchers have shown that flavokawain B, a kava chalcone, is about 4 to 12 fold more effective in reducing the cell viabilities of androgen receptor (AR)-negative, hormone-refractory prostate cancer cell lines DU145 and PC-3 than AR-positive, hormone-sensitive prostate cancer cell lines LAPC4 and LNCaP, with minimal effect on normal prostatic epithelial and stromal cells. [Int J Cancer]

    Gossypol Induces Apoptosis by Activating p53 in Prostate Cancer Cells and Prostate Tumor-Initiating Cells
    These studies show for the first time that gossypol treatment induces DNA damage and activates p53. [Mol Cancer Ther]

    CCR9-Mediates PI3K/AKT Dependent Anti-Apoptotic Signals in Prostate Cancer Cells and Inhibition of CCR9-CCL25 Interaction Enhances the Cytotoxic Effects of Etoposide
    Researchers show that CC chemokine receptor 9 and its natural ligand CCL25 interaction up regulates anti-apoptotic proteins and down regulate activation of caspase-3 in prostate cancer cells. [Int J Cancer]

    Inhibition of Glycogen Synthase Kinase-3(Beta) Promotes Nuclear Export of the Androgen Receptor through a CRM1-Dependent Mechanism in Prostate Cancer Cell Lines
    Results suggest that glycogen synthase kinase-3(beta) is an important element not only in androgen receptor (AR) stability but also significantly alters nuclear translocation of the AR, thereby modulating the androgenic response of human prostate cancer cells. [J Cell Biochem]

    CLINICAL RESEARCH

    Finasteride to Prevent Prostate Cancer: Should All Men or Only a High-Risk Subgroup Be Treated?
    Researchers sought to determine whether prostate-specific antigen levels could identify a high-risk subgroup for which the benefits of finasteride treatment outweigh the potential harms. [J Clin Oncol]

    Prognostic Parameters, Complications, and Oncologic and Functional Outcome of Salvage Radical Prostatectomy for Locally Recurrent Prostate Cancer after 21st-Century Radiotherapy
    Investigators evaluated preoperative prognostic risk factors to predict organ-confined, locally recurrent prostate cancer after primary radiotherapy. [Eur Urol]

    Watch Procedure Now 
    Optimized Enzymes and Protocols for
    Prostate Tissue Dissociation

    by STEMCELL Technologies
     
     
    CLICK HERE TO LEARN MORESTEMCELL Technologies Inc
     

    INDUSTRY NEWS

    Launch of Ipsen’s Decapeptyl® 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer
    Ipsen and Debiopharm Group announce the launch by Ipsen in France of Decapeptyl® LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer. [Business Wire]

    Progenics Presents Novel Multiplex PI3-Kinase Inhibitors at American Association for Cancer Research Conference on Protein Translation and Cancer
    Progenics Pharmaceuticals, Inc. announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells. [Progenics Pharmaceuticals Press Release]


    POLICY NEWS

    Notice of Availability of Administrative Supplements for R25 Science Education Grants (NOT-DA-10-007) [National Institutes of Health, United States]

    Recovery Act Limited Competition: Program to Enhance National Institutes of Health-Supported Global Health Research Involving Human Subjects (S07) (RFA-OD-10-006) [National Institutes of Health, United States]

    Institutional Clinical and Translational Science Award (U54) (RFA-RM-10-001) [National Institutes of Health, United States]

    Investigator Initiated Multi-Site Clinical Trials (Collaborative R01) (PAR-10-096) [National Heart, Lung, and Blood Institute, United States]

    NIDDK Centers of Excellence in Molecular Hematology (P30) (RFA-DK-09-013) [National Institute of Diabetes and Digestive and Kidney Diseases, United States]

    Public Consultation (MLX 366): Intention to Amend the Medicines for Human Use (Prescribing by EEA Practitioners) Regulations 2008 (SI 2008/1692) [The Medicines and Healthcare Products Regulatory Agency, United Kingdom]


    EVENTS

    SMi’s Second Annual Stem Cells 2010
    February 15-16, 2010
    London, United Kingdom

    Keystone Symposia: Stem Cell Differentiation and Dedifferentiation (B4)
    February 15-20, 2010
    Keystone, United States

    5th Annual Stem Cell Summit
    February 16, 2010
    New York, United States

    Third International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer
    February 24-27, 2010
    Washington, DC, United States

    The 3rd World Congress on Controversies in Urology (CURy)
    February 25-28, 2010
    Athens, Greece

    2010 Genitourinary Cancers Symposium: Progress in Multidisciplinary Management
    March 5-7, 2010
    San Francisco, United States

    American Association for Cancer Research (AACR) 101st Annual Meeting 2010
    April 17-21, 2010
    Washington, DC, United States

    American Urological Association (AUA) Annual Meeting
    May 29-June 2, 2010
    San Francisco, United States

    The 21st Meeting of the European Association for Cancer Research (EACR)
    June 26-29, 2010
    Oslo, Norway

    2010 World Cancer Congress 
    August 18-21, 2010
    Shenzhen, China


    JOB OPPORTUNITIES

    Business Development Europe – Cell Therapy Products (PALL Corporation)

    Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

    Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

    Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
    Visit here to post your career opportunities.


    Have we missed an important article or publication in Prostate Cell News? Click here to submit!

     

    Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us